AAIC 2025 Abstract·26 DecTRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer’s diseaseTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecLatest results from the dose‐expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer’s diseaseTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecInterim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s diseaseTrial in peopleInterventionsPaper